Vinorelbine Plus Paclitaxel in Treating Patients With Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
Withdrawn before enrolling · Phase 2
Conditions studied: Prostate Cancer
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of vinorelbine plus paclitaxel in treating patients with metastatic prostate cancer that is refractory to hormone therapy.
Key facts
- Study ID
- NCT00003622
- Run by
- James Ahlgren
- People needed
- 0
- Starts
- 1999-01-01
- Expected to finish
- 2017-02-22
- Last updated by the study team
- 2017-07-13
Who can join
Age: 18 and older, up to 120. Sex: male. Healthy volunteers: not accepted.
Where it is running
- George Washington University Hospital — Washington D.C., District of Columbia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.